These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

981 related articles for article (PubMed ID: 23996285)

  • 1. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).
    ; Rydén L; Grant PJ; Anker SD; Berne C; Cosentino F; Danchin N; Deaton C; Escaned J; Hammes HP; Huikuri H; Marre M; Marx N; Mellbin L; Ostergren J; Patrono C; Seferovic P; Uva MS; Taskinen MR; Tendera M; Tuomilehto J; Valensi P; Zamorano JL; ; Zamorano JL; Achenbach S; Baumgartner H; Bax JJ; Bueno H; Dean V; Deaton C; Erol C; Fagard R; Ferrari R; Hasdai D; Hoes AW; Kirchhof P; Knuuti J; Kolh P; Lancellotti P; Linhart A; Nihoyannopoulos P; Piepoli MF; Ponikowski P; Sirnes PA; Tamargo JL; Tendera M; Torbicki A; Wijns W; Windecker S; ; De Backer G; Sirnes PA; Ezquerra EA; Avogaro A; Badimon L; Baranova E; Baumgartner H; Betteridge J; Ceriello A; Fagard R; Funck-Brentano C; Gulba DC; Hasdai D; Hoes AW; Kjekshus JK; Knuuti J; Kolh P; Lev E; Mueller C; Neyses L; Nilsson PM; Perk J; Ponikowski P; Reiner Z; Sattar N; Schächinger V; Scheen A; Schirmer H; Strömberg A; Sudzhaeva S; Tamargo JL; Viigimaa M; Vlachopoulos C; Xuereb RG
    Eur Heart J; 2013 Oct; 34(39):3035-87. PubMed ID: 23996285
    [No Abstract]   [Full Text] [Related]  

  • 2. Comments on the ESC guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the european society for the study of diabetes.
    ; ;
    Rev Esp Cardiol (Engl Ed); 2014 Feb; 67(2):87-93. PubMed ID: 24795114
    [No Abstract]   [Full Text] [Related]  

  • 3. 2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: established knowledge and evidence gaps.
    Paneni F
    Diab Vasc Dis Res; 2014 Jan; 11(1):5-10. PubMed ID: 24254974
    [No Abstract]   [Full Text] [Related]  

  • 4. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary.
    ; ; Rydén L; Grant PJ; Anker SD; Berne C; Cosentino F; Danchin N; Deaton C; Escaned J; Hammes HP; Huikuri H; Marre M; Marx N; Mellbin L; Ostergren J; Patrono C; Seferovic P; Uva MS; Taskinen MR; Tendera M; Tuomilehto J; Valensi P; Zamorano JL
    Diab Vasc Dis Res; 2014 May; 11(3):133-73. PubMed ID: 24800783
    [No Abstract]   [Full Text] [Related]  

  • 5. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
    Cosentino F; Grant PJ; Aboyans V; Bailey CJ; Ceriello A; Delgado V; Federici M; Filippatos G; Grobbee DE; Hansen TB; Huikuri HV; Johansson I; Jüni P; Lettino M; Marx N; Mellbin LG; Östgren CJ; Rocca B; Roffi M; Sattar N; Seferović PM; Sousa-Uva M; Valensi P; Wheeler DC;
    Eur Heart J; 2020 Jan; 41(2):255-323. PubMed ID: 31497854
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular prevention in patients with diabetes and prediabetes.
    Anselmino M; Gohlke H; Mellbin L; Rydén L
    Herz; 2008 Apr; 33(3):170-7. PubMed ID: 18568310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).
    Rydén L; Standl E; Bartnik M; Van den Berghe G; Betteridge J; de Boer MJ; Cosentino F; Jönsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I; Vanhorebeek I; Stramba-Badiale M; Lindgren P; Qiao Q; Priori SG; Blanc JJ; Budaj A; Camm J; Dean V; Deckers J; Dickstein K; Lekakis J; McGregor K; Metra M; Morais J; Osterspey A; Tamargo J; Zamorano JL; Deckers JW; Bertrand M; Charbonnel B; Erdmann E; Ferrannini E; Flyvbjerg A; Gohlke H; Juanatey JR; Graham I; Monteiro PF; Parhofer K; Pyörälä K; Raz I; Schernthaner G; Volpe M; Wood D; ;
    Eur Heart J; 2007 Jan; 28(1):88-136. PubMed ID: 17220161
    [No Abstract]   [Full Text] [Related]  

  • 8. The Munich Myocardial Infarction Registry: translating the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines on diabetes, pre-diabetes, and cardiovascular disease into clinical practice.
    Schnell O; Otter W; Standl E
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S326-30. PubMed ID: 19875574
    [No Abstract]   [Full Text] [Related]  

  • 9. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).
    Perk J; De Backer G; Gohlke H; Graham I; Reiner Z; Verschuren M; Albus C; Benlian P; Boysen G; Cifkova R; Deaton C; Ebrahim S; Fisher M; Germano G; Hobbs R; Hoes A; Karadeniz S; Mezzani A; Prescott E; Ryden L; Scherer M; Syvänne M; Scholte op Reimer WJ; Vrints C; Wood D; Zamorano JL; Zannad F; ;
    Eur Heart J; 2012 Jul; 33(13):1635-701. PubMed ID: 22555213
    [No Abstract]   [Full Text] [Related]  

  • 10. Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus.
    Prausmüller S; Resl M; Arfsten H; Spinka G; Wurm R; Neuhold S; Bartko PE; Goliasch G; Strunk G; Pavo N; Clodi M; Hülsmann M
    Cardiovasc Diabetol; 2021 Feb; 20(1):34. PubMed ID: 33530999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the Steno T1 Risk Engine Identifies Preclinical Atherosclerosis Better Than Use of ESC/EASD-2019 in Adult Subjects With Type 1 Diabetes at High Risk.
    Serés-Noriega T; Giménez M; Perea V; Boswell L; Viñals C; Blanco J; Vinagre I; Pané A; Esmatjes E; Conget I; Amor AJ
    Diabetes Care; 2022 Oct; 45(10):2412-2421. PubMed ID: 35944257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New ESC guidelines 2019 "Diabetes, prediabetes and cardiovascular diseases" : Paradigm shift in reduction of cardiovascular risk in patients with diabetes mellitus].
    Marx N
    Herz; 2019 Dec; 44(8):684-687. PubMed ID: 31686123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ways to reduce cardiovascular disease in diabetes.
    Garg SK; DiDomenico D; Switzer S
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S1-2. PubMed ID: 22650219
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular disease (CVD) limbo: how soon and low should we go to prevent CVD in diabetes?
    Maahs DM
    Diabetes Technol Ther; 2012 Jun; 14(6):449-52. PubMed ID: 22472062
    [No Abstract]   [Full Text] [Related]  

  • 15. [ESC guidelines on diabetes, pre-diabetes and diseases of the cardiovascular system developed in cooperation with the EASD].
    ; Rydén L; Grant PJ; Anker SD; Berne C; Cosentino F; Danchin N; Deaton C; Escaned J; Hammes HP; Huikuri H; Marre M; Marx N; Mellbin L; Ostergren J; Patrono C; Seferovic P; Sousa Uva M; Taskinen MR; Tendera M; Tuomilehto J; Valensi P; Zamorano JL;
    Kardiol Pol; 2013; 71 Suppl 11():S319-94. PubMed ID: 24297732
    [No Abstract]   [Full Text] [Related]  

  • 16. The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen.
    Grant PJ; Cosentino F
    Eur Heart J; 2019 Oct; 40(39):3215-3217. PubMed ID: 31608951
    [No Abstract]   [Full Text] [Related]  

  • 17. [2016 European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts. Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation].
    Piepoli MF; Hoes AW; Agewall S; Albus C; Brotons C; Catapano AL; Cooney MT; Corrà U; Cosyns B; Deaton C; Graham I; Hall MS; Hobbs FDR; Løchen ML; Löllgen H; Marques-Vidal P; Perk J; Prescott E; Redon J; Richter DJ; Sattar N; Smulders Y; Tiberi M; van der Worp HB; van Dis I; Verschuren WMM
    G Ital Cardiol (Rome); 2017; 18(7):547-612. PubMed ID: 28714997
    [No Abstract]   [Full Text] [Related]  

  • 18. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
    Dziuba J; Alperin P; Racketa J; Iloeje U; Goswami D; Hardy E; Perlstein I; Grossman HL; Cohen M
    Diabetes Obes Metab; 2014 Jul; 16(7):628-35. PubMed ID: 24443793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiovascular prophylaxis through intensified insulin treatment. EDIC (Epidemiology of Diabetes Interventions and Complications)].
    Scherbaum WA
    Internist (Berl); 2006 Sep; 47(9):960-2. PubMed ID: 16868769
    [No Abstract]   [Full Text] [Related]  

  • 20. [Diabetes treatment of the move. Prevent cardiovascular catastrophe from the start].
    Nauck M
    MMW Fortschr Med; 2010 May; 152(18):36. PubMed ID: 20514761
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 50.